Amanda Pooler, M.A., LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 10 Commerce Park N, Unit 1a, Bedford, NH 03110 Phone: 603-606-1233 |
Keri Feole-casinelli, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 10 Commerce Park N Ste 13b, Bedford, NH 03110 Phone: 603-660-1233 |
Christine Beaudoin, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 85 South River Road Ste 1, Bedford, NH 03110 Phone: 603-714-5993 Fax: 603-471-3504 |
Ms. Diane Louise Vaccarello, M.S., LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 264 S River Rd, Bedford, NH 03110 Phone: 603-218-6073 |
Heather Torrens, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 116 S River Rd Unit E, Bedford, NH 03110 Phone: 978-226-8025 |
Benjamin Richard Long Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 173 S River Rd Ste 2, Bedford, NH 03110 Phone: 603-255-5267 |
News Archive
Findings on coronary CT angiography (CTA), a noninvasive test to assess the coronary arteries for blockages, show different risk scenarios for men and women, according to a study presented today at the Radiological Society of North America.
The Indian Heart Watch (IHW) study has revealed the truth behind the prevalence, awareness, treatment and control of key risk factors that are driving the country's growing cardiovascular disease (CVD) epidemic, in a first-of-a-kind presentation of data at the World Congress of Cardiology today.
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the first Xoft Axxent Electronic Brachytherapy (eBx) System in Spain is now available at the Hospital Miguel Servet for the treatment of early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.
Monitoring participants' biological clocks may be the quickest way to determine the effectiveness of experimental drugs currently under development to treat Angelman syndrome: a debilitating genetic disorder that occurs in more than one in every 15,000 live births.
› Verified 9 days ago